News

A new compound that becomes therapeutically active when stimulated by light was able to reverse motor symptoms in a mouse model of Parkinson’s disease. The distinctive features of this investigational compound, called MRS7145, include more control when delivering the therapy and fewer side effects. The study about MRS7145, “…

The U.S. Food and Drug Administration (FDA) has accepted for review its request to approve apomorphine sublingual film (APL-130277) as a quick-acting, oral treatment of the motor fluctuations, or off episodes, associated with Parkinson’s disease. Sunovion, which is developing the potential therapy, submitted a new drug application, or…

Accumulation of alpha-synuclein protein in the retina could be a biomarker of Parkinson’s disease severity, a new study suggests. The study, “Phosphorylated α‐synuclein in the retina is a biomarker of Parkinson’s disease pathology severity,” was published in the journal Movement Disorders. Non-motor symptoms of Parkinson’s disease include…

Mutations in the LRP10 gene are associated with the development of neurodegenerative diseases with Lewy bodies formation, such as Parkinson’s disease, Parkinson’s dementia and dementia with Lewy bodies, according to a recent study. The study, “LRP10 genetic variants in familial Parkinson’s disease and dementia with…

Mutations in two specific genes affect how nerve cells work in the brain, disrupting sleep patterns in Parkinson’s patients, a new study suggests, and recommends a way of possibly treating this disease symptom. The research, “ER Lipid Defects in Neuropeptidergic Neurons Impair Sleep Patterns in Parkinson’s Disease,” appeared in…

Laurie Mischley, PhD, a researcher at the private, non-profit Bastyr University, is launching the first-ever summer school program for Parkinson’s disease patients. This August, Mischley will facilitate two medical-educational retreats at Bastyr as part of the new “PD Summer School.” Until June 15 those interested can apply…

A form of vitamin B3 can prevent degeneration and death of nerve cells linked to Parkinson’s and other neurodegenerative diseases. The study with that finding, “The NAD+ precursor, nicotinamide riboside, rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson’s disease,” was published in …

The controversy surrounding Nuplazid (pimavanserin), Acadia Pharmaceuticals‘ approved treatment for psychosis in Parkinson’s patients, has made its way to scientific journals. But experts appear to take a more questioning view of the medication’s risks than that aired by general media. A clinical trial comparing the effectiveness and benefits of Nuplazid to…

Taking long daytime naps — rather than being excessively sleepy during day hours but not napping — appeared to be linked to a two-times higher risk of Parkinson’s disease in older men in a long-term study. The study, “Excessive daytime sleepiness, objective napping and 11-year risk of Parkinson’s disease…

Axovant Sciences licensed the exclusive worldwide rights from Oxford BioMedica to develop and market AXO-Lenti-PD, a gene therapy candidate for Parkinson’s disease. Formerly known as OXB-102, AXO-Lenti-PD uses a modified, harmless type of virus called lentivirus to deliver three genes that provide instructions to make a…